CellaVision AB Year-end bulletin, Jan-Dec 2018 - Seite 3

Innovation
Development of our new technology platform, the CellaVision DC-1 for small and mid-size laboratories, is now completed and the product was given CE marking in February 2019. We have carried out careful launch preparations and are now starting commercialization of this strategically important product. It is important to remember that 2019 will be a launch year. From initially low sales volumes we expect to see continual growth in sales of the CellaVision DC-1 in coming years.

During the quarter we acquired a system for blood smears from the Swedish company Molek. This technology acquisition means that we will supplement our offer with blood sample preparation, which is an important component to ensure high quality in our systems' image analysis. The system, to be called CellaVision Diffsmear, will be optimized in 2019 for use together with our analyzing systems. 

Distribution expansion
During the year we signed agreements with all relevant distribution partners to reach small and mid-size laboratories globally and thus are well prepared for the launch of the CellaVision DC-1. 

Investments in continued growth
Geographical expansion and innovation are key strategies for CellaVision's future growth. We are continuing to add new geographical markets with their own local organization for market support, while innovation and product development are gaining growing significance. Our organization is constantly being strengthened and we put great energy into recruiting leading-edge expertise to ensure our future innovative power, thus further strengthening our growth opportunities. 

Zlatko Rihter,
President and CEO

 

Key Ratios

(MSEK)	Oct-Dec 2018	Oct-Dec 2017	Full year 2018	Full year 2017
Net sales	111,0	76,1	364,8	309,3
Gross profit	82,0	55,4	270,9	223,2
EBITDA	37,3	23,9	118,4	99,3
Operating profit	35,8	21,7	111,6	90,9
Operating margin, %	32,3	28,5	30,6	29,4
Profit/loss before tax	36,0	21,7	112,1	90,3
Total cash flow	4,3	25,5	14,4	22,4
Equity ratio, %	77,9	80,1	77,9	80,1